Global Regulatory News
The Steering Committee (SC) agreed on the key issues relating to the reform of ICH in terms of governance, new membership and funding. ICH remains committed to enhanced communication, transparency and the openness of ICH to all relevant stakeholders. The SC will now proceed with finalizing the Articles of Association and funding model that will allow the ICH parties to carry out their internal consultations, which will pave the way toward establishing ICH as a legal entity as an international association under Swiss law. Membership in the Assembly, which will be the overarching body of the Association, will be established as soon as the legal entity has been set up.
The TGA Business Plan 2014-2015, provides an overview of the organisation’s strategic considerations including the mission, key roles and responsibilities, priorities and areas of particular emphasis, and significant changes and challenges.
The Australian Government is planning a review of the regulation of medicines and medical devices. The Review will be conducted by a panel of three experts: Emeritus Professor Lloyd Sansom AO, Will Delaat AM, and Professor John Horvath AO. The Review will examine specific aspects of the regulatory framework for medicines and medical devices administered by the Therapeutic Goods Administration with a view to identifying:
• Areas of unnecessary, duplicative, or ineffective regulation that could be removed or streamlined without undermining the safety or quality of therapeutic goods available in Australia.
• Opportunities to enhance the regulatory framework so that Australia continues to be well positioned to respond effectively to global trends in the development, manufacture, marketing and regulation of therapeutic goods.
The China Food and Drug Administration (CFDA) has issued the Third Supplement to the Chinese Pharmacopeia (2010 edition) that will go into force as of 1 February 2015. The Third Supplement makes improvements in testing technology, impurity control and other aspects.
On 21 November 2014, Wu Zhen, Vice Minister of China Food and Drug Administration (CFDA) met with the delegation headed by Dr. Margaret Hamburg, Commissioner of the US Food and Drug Administration (FDA). Both sides exchanged opinions on topics of common concerns such as further deepening of China-US cooperation in drug supervision, mutual cooperation and support in relevant international organizations, and the exchange of regulatory staff.
Major points of the amendments to the Ministerial Ordinance on Standards for Manufacturing Control and Quality Control for Medical Devices and In-Vitro Diagnostics include:
1. Harmonizing the 2nd chapter of the ordinance with ISO13485: 2003
2. Describing the additional requirements to ISO13485:2003 in the 3rd chapter of the ordinance
Currently, the legislative controls for pharmaceutical products are covered under different Acts, namely the Medicines Act (Cap. 176) and Poisons Act (Cap. 234). Consolidating the relevant controls under the HPA will provide greater clarity to stakeholders as they would only need to refer to a single legislation.
The European Medicines Agency (EMA) has released a practical guide detailing the process for requesting access to unpublished documents held by the Agency. The guide details in particular:
• How a request is processed
• How the documents are provided
• In which cases access can be refused
• How a requester can appeal EMA’s decision to refuse access to documents
The European Medicines Agency’s (EMA) Management Board held a meeting on 27 November 2014 in Rome, Italy to discuss the consequences of the judgment by the European Union Civil Service Tribunal that annulled the appointment of the Agency’s Executive Director Guido Rasi.
The Management Board chaired by Sir Kent Woods confirmed that Deputy Executive Director Andreas Pott will be in charge of the management and operations of the Agency until the new selection procedure suggested by the European Commission is finalized. The European Commission plans to publish a vacancy announcement for the post of Executive Director shortly.
The European Medicines Agency (EMA) has released a practical guide detailing the process for requesting access to unpublished documents held by the Agency. As foreseen by European Union law and detailed in the EMA’s 2010 access-to-documents policy, citizens can have access to documents held by EMA. The guidance can be found here .
The European Medicines Agency (EMA) has published its revised policy on handling declarations of interests for scientific committee members and experts. The revisions reflect a more balanced approach to handling conflicts of interests that aims to effectively restrict the involvement of experts with possible conflicts of interests in the Agency’s work while maintaining EMA’s ability to access the best available expertise.
The revised policy, which was endorsed by the EMA Management Board in March 2014, takes into account input from stakeholders at the Agency’s September 2013 public workshop “Best expertise vs conflicts of interests: striking the right balance.”
The Medicines and Healthcare Products Regulatory Agency has appointed Professor Sir Michael Rawlins as its new Chair effective 1 December 2014 and his appointment will be for three years. Professor Sir Michael assumes the role from Sir Gordon Duff who announced his intention to step down earlier this year, following his election as Principal of St Hilda’s College, Oxford. Professor Sir Michael Rawlins was until recently Chair of the National Institute of Health and Clinical Excellence (NICE), a role from which he stood down in 2013. He is also currently Chairman of Biobank.
The FDA has issued three additional policy documents to assist entities that compound sterile human drugs with registering as outsourcing facilities. The policy documents also will assist entities with complying with provisions of the Drug Quality and Security Act (DQSA), which was enacted in November 2013.
This guidance provides recommendations intended to assist in determining which reporting mechanism is appropriate for submission of changes to an approved Biologics License Application (BLA) in accordance with the requirements under Title 21 of the Code of Federal Regulations (CFR) 601.12 (21 CFR 601.12), including recommendations in connection with the applicability and content of comparability protocols under 21 CFR 601.12(e) and labeling changes under 21 CFR 601.12(f).
The Food and Drug Administration Safety and Innovation Act added a provision to the Food, Drug, and Cosmetic Act concerning inspections that makes a drug adulterated. This guidance defines the types of actions, inaction, and circumstances that FDA considers to constitute delaying, denying, or limiting inspection, or refusing to permit entry or inspection for the purposes of making a drug adulterated.
FDA Issues “Draft Guidance for Industry: The Effect of Section 585 of the FD&C Act on Drug Product Tracing and Wholesale Drug Distributor and Third-Party Logistics Provider Licensing Standards and Requirements: Questions and Answers”
The FDA is issuing this guidance to assist stakeholders in understanding the effects of section 585 (Uniform National Policy) of the Food Drug and Cosmetic Act, which was added by the Drug Supply Chain Security Act (DSCSA). The DSCSA establishes a Federal system for tracing prescription drug products through the pharmaceutical distribution supply chain. It also requires FDA to establish federal standards for licensing of wholesale drug distributors and third party logistics providers. Section 585 sets forth a uniform national policy preempting states from establishing or continuing in effect certain standards and requirements related to prescription drug product tracing and licensing, wholesale distributors and third-party logistics providers.
The US Food and Drug Administration published a final rule that sets standards for how information about using medicines during pregnancy and breastfeeding is presented in the labeling of prescription drugs and biological products. The new content and formatting requirements will provide a more consistent way to include relevant information about the risks and benefits of prescription drugs and biological products used during pregnancy and breastfeeding.
In a blog post, FDA Commissioner Margaret Hamburg outlined challenges facing the FDA and an effort of Program Alignment to meet these challenges. The challenges include an increased breath and complexity of FDA’s mandate, the impact of globalization on supply chains, and the rapid scientific innovation and increased biomedical diversity. The Directorates, Centers and the Office of Regulatory Affairs (ORA) have collaborated closely to define the changes needed to align the Agency more strategically and operationally and meet the greater demands placed on it. Each regulatory program has defined new action plans which will provide focus for the year 2015, and in some cases require additional 5 year plans to be developed.
The FDA has published the fiscal year 2015 regulatory science priorities for generic drugs. The FY 2015 research priorities list was prepared based on comments received at the 16 May 2014, public meeting, comments submitted to the public docket, scientific issues raised in citizen petitions, meeting request and controlled correspondence topics, tracked safety issues and discussions within FDA’s Center for Drug Evaluation and Research. To comply with this GDUFA requirement, the FDA Office of Generic Drugs developed the following fiscal year 2015 regulatory science priorities for generic drugs:
• Post-market evaluation of generic drugs
• Equivalence of complex products
• Equivalence of locally-acting products
• Therapeutic equivalence evaluation and standards
• Computational and analytical tools